NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading VCEL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 23% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, margins, the balance sheet.
View ManagementExpectations look high — the market is pricing in about 36% growth a year, above the roughly 18% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 31% in its worst 12-month stretch.
View RiskVericel's growth in the healthcare sector must continue to justify its current price. Recent financial performance has been strong, with a notable beat of 25% last quarter. It trades at 8.3 times price-to-sales, while the peer median is 8.7 times. The market is pricing in more growth than expected, indicating full expectations. If Vericel cuts guidance on the next call, it could negatively impact the stock. Peer multiples imply a price about 40% below where it trades; this read is provisional.
Trailing returns as of 2026-07-31. VCEL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering VCEL (as of Jul 2026).
Based on 3 Wall Street analysts offering 12-month price targets for VCEL in the last 4 months.
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Advances: Increase MACI revenue growth
20% revenue jump supports MACI growth objective.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $45.96
The last 12 months of price, then the range of analyst 12-month targets from today’s $45.96.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase MACI revenue growth
20% revenue jump supports MACI growth objective.
Advances: Achieve high revenue and profit growth
Forecasting strong revenue growth aligns with profit objectives.
Advances: Achieve high revenue and profit growth
Raising guidance indicates strong profit growth potential.
Advances: Expand Burn Care revenue
BARDA award enhances Burn Care revenue expansion.
Advances: Achieve high revenue and profit growth
FDA approval supports high revenue and profit growth.
Advances: Increase MACI revenue growth
Sales force expansion expected to boost MACI revenue.
Threatens: Expand Burn Care revenue
Waning Burn Care revenue poses a challenge.
